Friday, 14 December 2018
Latest news
Main » ACADIA Pharmaceuticals (ACAD) Earns Daily Coverage Optimism Score of 0.17

ACADIA Pharmaceuticals (ACAD) Earns Daily Coverage Optimism Score of 0.17

19 January 2018

ACADIA Pharmaceuticals's quarterly revenue was up 571.3% compared to the same quarter last year. equities analysts anticipate that ACADIA Pharmaceuticals will post -2.41 earnings per share for the current year. According to the latest data, the consensus recommendation for ACADIA Pharmaceuticals Inc.

The company had seen its current volume reaching at 0.87 million shares in the last trade. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.0341317405821 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. 2017, ACADIA Pharmaceuticals Inc. It has underperformed by 19.60% the S&P500.

Kentucky Retirement Systems increased its stake in Oneok Inc New (OKE) by 72.47% based on its latest 2017Q3 regulatory filing with the SEC. (NYSE:OKE). The California-based Wells Fargo & Mn has invested 0.02% in ONEOK, Inc. JPMorgan Chase & Co. raised its position in shares of ACADIA Pharmaceuticals by 5.4% in the second quarter. Agf Investments Inc who had been investing in Royal Bank Of Canada for a number of months, seems to be less bullish one the $122.87B market cap company. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. About 6.61 million shares traded. It has outperformed by 7.11% the S&P500. The shares were sold at an average price of $30.14, for a total transaction of $2,240,034.94. There were 25 sold out positions, on the other hand, totaling 1,769,722 shares. Swiss National Bank holds 0.01% or 162,904 shares in its portfolio. Therefore 25% are positive. The stock has "Reduce" rating by Nomura on Tuesday, February 23. The firm has "Hold" rating given on Tuesday, May 3 by Canaccord Genuity. (NYSE:OKE) has "Underperform" rating given on Thursday, January 12 by Jefferies. As per Thursday, November 2, the company rating was maintained by Jefferies. Zacks Investment Research lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, October 16th.

Ratings analysis reveals 75% of ACADIA Pharmaceuticals's analysts are positive.

Additionally, according to the most recent 13F filing from ACADIA Pharmaceuticals Inc. The stock presently has a consensus rating of "Buy" and an average target price of $48.86. The firm earned "Buy" rating on Thursday, July 27 by Jefferies. RBC Capital Markets downgraded Barrick Gold Corporation (NYSE:ABX) on Wednesday, November 1 to "Sector Perform" rating.

Ownership at ACADIA Pharmaceuticals Inc. The firm has "Overweight" rating given on Friday, January 22 by Piper Jaffray. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. (NYSE:OKE) has "Buy" rating given on Monday, January 11 by Argus Research. The company was maintained on Wednesday, August 9 by H.C. Wainwright. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $49.00 target price on shares of ACADIA Pharmaceuticals in a report on Sunday, September 17th. Piper Jaffray maintained it with "Buy" rating and $5400 target in Wednesday, August 9 report. Cowen & Co maintained the shares of ACAD in report on Wednesday, October 4 with "Buy" rating. The firm earned "Hold" rating on Monday, June 19 by RBC Capital Markets.

Taking a look at a stock's average volume - in the long, medium and short terms - is helpful for understanding investor sentiment and trading activity.

Currently, the stock carries a price to earnings ratio of 14.08, a price to book ratio of 1.48, and a price to sales ratio of 0.71. 32 funds opened positions while 52 raised stakes. Sectoral Asset Management Inc now owns 1,098,809 shares of the biopharmaceutical company's stock valued at $30,646,000 after purchasing an additional 427,696 shares in the last quarter. (NASDAQ:ACAD). Invsts reported 2.55 million shares stake. (NASDAQ:ACAD) for 155,811 shares. Garrison Bradford & has invested 2.31% of its portfolio in ACADIA Pharmaceuticals Inc. It also upped Abiomed Inc (NASDAQ:ABMD) stake by 51,253 shares and now owns 120,147 shares. Emerald Mutual Fund Advisers Trust, a Pennsylvania-based fund reported 225,409 shares. North Star Mngmt has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Senator Invest Group Ltd Partnership owns 1.44M shares or 0.72% of their United States portfolio. Alliancebernstein LP reported 98,437 shares or 0% of all its holdings. D E Shaw Com Inc accumulated 18,429 shares or 0% of the stock. Rhumbline Advisers accumulated 111,094 shares. Macquarie Group Inc Ltd reported 78,810 shares. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.19% since January 19, 2017 and is downtrending.